Is satelizumab (Anshiping) a targeted drug?

Satralizumab (Satralizumab) is a monoclonal antibody used to treat idiopathic neuromyelitis optica (NMOSD). Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system (CNS) characterized by inflammatory and demyelinating lesions of the optic nerve, spinal cord, brainstem, and brain, leading to progressive impairment of vision and motor function. Satralizumab is a disposable prefilled syringe containing 120 mg/mL satralizumab for subcutaneous injection. Recent studies have shown that interleukin-6 (IL-6) plays an important role in the immune pathogenesis of NMOSD.